Clinical Trial Update: Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) [Phase 1]

View source ↗

Summary

Phase 1 trial update for VSV-EBOV vaccine (V920) in healthy adults, reporting dose response and safety/immunogenicity results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• VESicular Stomatitis Virus Ebola Vaccine (VSV-EBOV) vaccine (rVSV-ZEBOV)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ebola Virus | Phase 1 | Status: COMPLETED | Results posted: 2020-01-02